ライフサイエンスコーパス: atorvastatin

1 transcellular biosynthesis and increased by atorvastatin.

2 and human liver cirrhosis and was blunted by atorvastatin.

3 ibed antihyperlipidemic drugs, ezetimibe and atorvastatin.

4 and identified synergy between rapamycin and atorvastatin.

5 ng therapy with fluvastatin, pravastatin, or atorvastatin.

6 e increased 20.8+/-141.1 U/L (P<0.0001) with atorvastatin.

7 ; P = 0.01) compared with those who received atorvastatin.

8 lar events in patients treated with low-dose atorvastatin.

9 mic effects which are comparable to those of atorvastatin.

10 mpared the efficacy of high- versus low-dose atorvastatin.

11 synthesis of the cholesterol lowering agent, atorvastatin.

12 -density lipoprotein cholesterol levels with atorvastatin.

13 statins, the primary metabolites of the drug atorvastatin.

14 locumab by a mechanism distinct from that of atorvastatin.

15 aseline and after 12 weeks of treatment with atorvastatin.

16 iltration rate <60 mL/min/1.73 m2) receiving atorvastatin.

17 inistration of 2 clinically relevant statins-atorvastatin (0.2 mg/kg) or pravastatin (0.2 mg/kg)-to m

18 Considering the type of statin used, atorvastatin (0.51; 0.41-0.64), pravastatin (0.40; 0.28-

19 In the in vitro model, pretreatment with atorvastatin (1) prevented CM-induced renal cell apoptos

20 14.42% [8.7% to 19.8%]; p < 0.001), but not atorvastatin 10 mg (% reduction: 4.2% [-2.3% to 10.4%];

21 additional relative reductions in TBR versus atorvastatin 10 mg (10.6% [2.2% to 18.3%]; p = 0.01) at

22 as early as 4 weeks after randomization with atorvastatin 10 mg (6.4% reduction, p < 0.05) and 80 mg

23 utcomes in the group randomized to remain on atorvastatin 10 mg (p = 0.039), but not in the group tha

24 tatin 80 mg group and in 148 of 4,418 in the atorvastatin 10 mg and simvastatin 20 to 40 mg groups (3

25 statin was shown), all patients were offered atorvastatin 10 mg daily open label.

26 treated for angina were randomly assigned to atorvastatin 10 mg daily or matching placebo in a random

27 After a run-in period with atorvastatin 10 mg daily, patients were randomized to ei

28 borative Atorvastatin Diabetes Study (CARDS; atorvastatin 10 mg versus placebo) of 3878 and 2838 pati

29 an Cardiac Outcomes Trial (ASCOT-LLA) study (atorvastatin 10 mg versus placebo) were used for model d

30 sterol <130 mg/dL randomized to double-blind atorvastatin 10 or 80 mg/d in the Treating to New Target

31 gh-dose statins (n = 83), were randomized to atorvastatin 10 versus 80 mg in a double-blind, multicen

32 -C >/=100 mg/dl (2.59 mmol/l) on stable-dose atorvastatin 10, 20, or 40 mg for >/=6 weeks to: subcuta

33 y randomized to a daily, moderate-intensity (atorvastatin [10 mg], simvastatin [40 mg], or rosuvastat

34 r matching placebo; 10 mg TA-8995 plus 20 mg atorvastatin; 10 mg TA-8995 plus 10 mg rosuvastatin or 2

35 tal vein ligation/PPVL) rats received either atorvastatin (15 mg/kg; 7d) or control chow before sacri

36 olesterol was lower in patients treated with atorvastatin (2.4 [0.07] vs. 2.6 [0.06] mmol/L; P = 0.00

37 astatin 80 mg), 28.6% moderate-dose statins (atorvastatin 20-<40 mg, rosuvastatin 10-<20 mg, simvasta

38 with severe sepsis were administrated either atorvastatin (20 mg daily) or matched placebo.

39 not initially receiving a statin were given atorvastatin, 20 mg, and the following LLT intensificati

40 lial hypercholesterolemia who were receiving atorvastatin (21 subjects) and those with nonfamilial hy

41 bed with NOACs over all person-quarters were atorvastatin (27.6%), diltiazem (22.7%), digoxin (22.5%)

42 sterolemia who were receiving treatment with atorvastatin (30 subjects) (baseline LDL cholesterol, >1

43 Simvastatin 40 mg and atorvastatin 40 mg accounted for 23.1% and 22.8% of all

44 s for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of m

45 th an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about pound2 per month

46 e randomized to receive 3-day treatment with atorvastatin 40 mg/d or placebo before surgery.

47 d a randomized placebo-controlled trial with atorvastatin 40 mg/day for 9 weeks in 14 SPG5 patients w

48 High-intensity statins included atorvastatin 40 or 80 mg and rosuvastatin 20 or 40 mg.

49 High-intensity statins included atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg, and

50 Overall, 58.4% received high-dose statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg, simvastati

51 Atorvastatin (40 mg per day orally) was administered to

52 f tacrolimus, short-course methotrexate, and atorvastatin (40 mg per day orally).

53 low cholesterol intake (<300 mg/d; n=15) or atorvastatin (40 mg/d; n=15).

54 Oral atorvastatin, 40 mg/day for 21 days, was used routinely

55 filled a high-intensity statin prescription (atorvastatin, 40-80 mg, and rosuvastatin, 20-40 mg) with

56 enal and urinary AEs among patients assigned atorvastatin (481 [1.87%] per annum vs 392 [1.51%] per a

57 1.6+/-2.6% among those who received 10 mg of atorvastatin, 56.8+/-5.3% among those who received 80 mg

58 was significantly reduced from baseline with atorvastatin 80 mg (% reduction [95% confidence interval

59 MIRACL included 1,501 patients treated with atorvastatin 80 mg daily beginning 1 to 4 days after ACS

60 patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months.

61 OD developed in 142 of 4,407 patients in the atorvastatin 80 mg group and in 148 of 4,418 in the ator

62 actors, NOD developed in 448 of 3,128 in the atorvastatin 80 mg group and in 368 of 3,103 in the lowe

63 group versus 63 (57%) of 110 patients in the atorvastatin 80 mg group; renal events occurred in nine

64 of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups.

65 In this analysis, atorvastatin 80 mg lowered UPCR significantly more than

66 r filtration rate, and treatment status (ie, atorvastatin 80 mg or 10 mg).

67 pacity, and muscle strength before and after atorvastatin 80 mg or placebo was administered for 6 mon

68 Atorvastatin 80 mg resulted in significant additional re

69 ontal inflammation in patients randomized to atorvastatin 80 mg vs. 10 mg (DeltaTBR 80 mg vs. 10 mg g

70 taking high-dose statins were randomized to atorvastatin 80 mg vs. 10 mg in a multicenter, double-bl

71 io was 0.87 (95% CI 0.77-0.99; p=0.033) with atorvastatin 80 mg, 1.02 (0.88-1.18; p=0.83) with rosuva

72 We randomly assigned participants to atorvastatin 80 mg, rosuvastatin 10 mg, or rosuvastatin

73 aseline and after 16 weeks of treatment with atorvastatin 80 mg/d or placebo.

74 Compared with lower-dose statin therapy, atorvastatin 80 mg/day did not increase the incidence of

75 ts, SD and ASV were significantly lower with atorvastatin 80 mg/day versus 10 mg/day (SD: 12.03 +/- 9

76 Targets) trial, randomly assigned to receive atorvastatin 80 mg/day versus 10 mg/day and with at leas

77 Subanalysis of a randomized study of atorvastatin 80 mg/day versus pravastatin 40 mg/day for

78 10 mg, 124 to rosuvastatin 40 mg, and 111 to atorvastatin 80 mg; of these, 325 were included in the i

79 d a 2-by-2 factorial trial of the effects of atorvastatin (80 mg daily) and subcutaneous evolocumab (

80 ndomly allocated to receive either high-dose atorvastatin (80 mg) or a placebo, given orally once a d

81 , or rosuvastatin [5 mg]) or high-intensity (atorvastatin [80 mg], rosuvastatin [40 mg]) statin.

82 ification steps were applied: uptitration to atorvastatin, 80 mg; add-on ezetimibe therapy; add-on al

83 a heterogeneous response to the treatment of atorvastatin; a significant fraction of, but not all, th

84 The study provides the first evidence that atorvastatin acutely and simultaneously decreases oxidat

85 A single high loading dose of atorvastatin administered within 24 hours before CM expo

86 A novel two-pronged strategy of atorvastatin administration in both donors and recipient

87 Atorvastatin administration in healthy donors and recipi

88 Compared with baseline, atorvastatin administration in sibling donors was associ

89 itro study was also performed to see whether atorvastatin affects platelet oxidative stress and activ

90 ression, and used pharmaceutical inhibitors, atorvastatin, alendronate or zaragozic acid to inhibit t

91 The treatment of ezetimibe or atorvastatin alone decreased effectively the deposition

92 cholesterol than that attained with 80 mg of atorvastatin alone.

93 Atorvastatin also increased average creatine kinase, sug

94 ike mouse with the cholesterol-lowering drug atorvastatin ameliorated the pathology, implicating stat

95 those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all com

96 19 patients were assigned to atorvastatin and 21 to placebo.

97 49 participants assigned to torcetrapib plus atorvastatin and 223 participants assigned to atorvastat

98 Of 420 patients, 194 received atorvastatin and 226 pravastatin; the median low-density

99 30 individuals were assigned atorvastatin and 30 were allocated placebo.

100 Modulation of CQ-induced cell death by atorvastatin and cholesterol is reproduced across numero

101 HLA-mismatched mouse cardiac transplant with atorvastatin and dasatinib and showed reduction of the C

102 ature suggested that two FDA-approved drugs (atorvastatin and dasatinib), approved for nontransplant

103 Atorvastatin and evolocumab independently accelerated th

104 Atorvastatin and fluvastatin were associated with the mo

105 r placebo daily for 16 weeks, in addition to atorvastatin and other established therapies.

106 ncentrations (primary end point) between the atorvastatin and placebo groups (P = 0.76) and no intera

107 gment of the aorta was not different between atorvastatin and placebo, but technically adequate resul

108 We also found that atorvastatin and pravastatin each reduced systemic leuko

109 ns mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.

110 RvTs in mediating the protective actions of atorvastatin and pravastatin in reducing local and vascu

111 Atorvastatin and pravastatin produced significant reduct

112 ipoprotein change was -53.3% and -28.3% with atorvastatin and pravastatin, respectively (p < 0.001).

113 Mechanistically, atorvastatin and rapamycin activated a protein kinase Ca

114 ynergy was reproduced in vivo, in which only atorvastatin and rapamycin therapy in combination was su

115 genomic and clinical variables to avoid high atorvastatin and rosuvastatin levels is described; furth

116 dds of discontinuations with higher doses of atorvastatin and rosuvastatin.

117 The actions of atorvastatin and RvTs were additive in E. coli infection

118 dontitis groups (n = 90), systemic and local atorvastatin and saline were administered in three diffe

119 6.8+/-5.3% among those who received 80 mg of atorvastatin, and 48.5+/-5.2% among those who received a

120 y 68.2% in patients given 10 mg TA-8995 plus atorvastatin, and by 63.3% in patients given rosuvastati

121 nue with 10 mg or be up-titrated to 80 mg of atorvastatin, and followed during 5 years for major card

122 wastewater treatment plant where fluoxetine, atorvastatin, and sertraline were detected in fish bile

123 ins of R. oryzae were exposed to lovastatin, atorvastatin, and simvastatin and the minimum inhibitory

124 Black-box warnings, generic availability of atorvastatin, and updated guidelines may have resulted i

125 -9 immunoreactivity, with systemic and local atorvastatin application during and after induction of e

126 e first time, the role of systemic and local atorvastatin application on periodontium using histomorp

127 Systemic and local atorvastatin application showed beneficial effects on pe

128 Local atorvastatin application showed better results on period

129 rived risk increased in the torcetrapib plus atorvastatin arm compared with the atorvastatin-only arm

130 were examined in the dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Redu

131 The atorvastatin-assigned group showed a significant and pro

132 owering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a

133 y, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at

134 plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin a

135 We conducted a comparative evaluation of Atorvastatin (AT) versus the non-statin cholesterol-lowe

136 to determine the effects of a model statin, atorvastatin (ATO), on the proliferation and differentia

137 tions to a greater extent than did high-dose atorvastatin, atorvastatin seems to have more renoprotec

138 reatment of either placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks.

139 Rosuvastatin (RSV) and atorvastatin (ATV) are known to inhibit osteoclastic bon

140 s designed to evaluate effectiveness of 1.2% atorvastatin (ATV) gel, as an adjunct to scaling and roo

141 Atorvastatin (ATV) has shown pleiotropic effects on bone

142 Rosuvastatin (RSV) and atorvastatin (ATV) have shown bone stimulatory and anti-

143 Atorvastatin (ATV) is a specific competitive inhibitor o

144 second-generation platelet concentrate, and atorvastatin (ATV), a potent member of the statin group,

145 eased hs-CRP level were randomly assigned to atorvastatin-based standard medical therapy or standard

146 Moreover, atorvastatin blocked the non-canonical Hh-pathway RhoA d

147 identify patients having symptoms only with atorvastatin but not placebo.

148 occurred in 209 of 491 (42.6%) while taking atorvastatin but not while taking placebo.

149 of muscle strength or exercise capacity with atorvastatin, but more atorvastatin than placebo subject

150 Atorvastatin, but not placebo, reduced serum 27-hydroxyc

151 change from baseline was significant in the atorvastatin, but not the pravastatin group (p < 0.001 a

152 CONTEXT: Atorvastatin calcium (ATV), a cholesterol-lowering agent

153 t 70 mg/dL and by statin intensity (maximal: atorvastatin calcium, 80 mg/d, or rosuvastatin, 40 mg/d;

154 ients who were randomized to the addition of atorvastatin compared with those who were switched from

155 Atorvastatin concentration was associated with SLCO1B1 c

156 Atorvastatin consistently significantly reduced all-caus

157 randomised controlled trial to establish if atorvastatin could reduce cough in patients with bronchi

158 astatin the morning of surgery, and 40 mg of atorvastatin daily following surgery (n = 102) or matchi

159 Atorvastatin decreased portal pressure, shunt flow and a

160 Evolocumab but not atorvastatin decreased the production rate of intermedia

161 ederation of Neurological Surgeons patients, atorvastatin decreases serum levels of S100B, a biomarke

162 gions could be assessed in only 21 patients (atorvastatin Delta -0.03, 95% CI -0.17 to 0.12, vs place

163 ) atorvastatin group (NSPT plus medicated 2% atorvastatin dentifrice) and 2) placebo group (NSPT plus

164 n 40 mg versus usual care) and Collaborative Atorvastatin Diabetes Study (CARDS; atorvastatin 10 mg v

165 ion profiles revealed an enhanced removal of atorvastatin-diclofenac-hydrochlorothiazide (during the

166 as significantly lower for concurrent use of atorvastatin, digoxin, and erythromycin or clarithromyci

167 NOAC with or without concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone;

168 In vitro experiments demonstrated that atorvastatin dose-dependently inhibited platelet Nox2 an

169 gated in 26 RAA samples that were exposed to atorvastatin ex vivo.

170 Atorvastatin exerted a profound antioxidative effect on

171 Atorvastatin exerted significant antiatherogenic effects

172 cumulation and oxidation of vascular lipids, atorvastatin expedited the clearance of vascular lipids.

173 These results indicate that high-dose atorvastatin for 6 months does not decrease average musc

174 ter) or higher after treatment with 10 mg of atorvastatin for at least 7 weeks.

175 posure) occurred in 9 of 202 patients in the atorvastatin group (4.5%) and in 37 of 208 patients in t

176 ) II trial were randomly assigned to (1) the atorvastatin group (80 mg within 24 hours before contras

177 l was performed with two parallel groups: 1) atorvastatin group (NSPT plus medicated 2% atorvastatin

178 patients in this analysis (5101 [50%] in the atorvastatin group and 5079 [50%] in the placebo group),

179 f sites with CAL >/=5 mm, BOP, and GI in the atorvastatin group compared with the placebo group.

180 isk plaques was significantly reduced in the atorvastatin group compared with the placebo group: chan

181 12 (40%) of 30 patients in the atorvastatin group improved by 1.3 units or more on the

182 CIAKI rate was lower in the atorvastatin group in both diabetics and nondiabetics an

183 In the atorvastatin group of MIRACL, short-term risk increased

184 The atorvastatin group showed a decrease of 297.63 mm(2) in

185 9), AKI occurred in 22 of 102 (21.6%) in the atorvastatin group vs 13 of 97 (13.4%) in the placebo gr

186 6), AKI occurred in 42 of 206 (20.4%) in the atorvastatin group vs 47 of 210 (22.4%) in the placebo g

187 5), AKI occurred in 64 of 308 (20.8%) in the atorvastatin group vs 60 of 307 (19.5%) in the placebo g

188 90th percentile, -0.11 to 0.56 mg/dL) in the atorvastatin group vs by a median of 0.05 mg/dL (10th-90

189 f 36 individuals participated in this study (atorvastatin group, n = 18; placebo group, n = 18).

190 parately in the placebo group but not in the atorvastatin group.

191 Ten (33%) patients assigned atorvastatin had an adverse event versus three (10%) all

192 educed total and ABCA1-specific CEC, whereas atorvastatin had no significant effect.

193 n patients receiving 10 mg TA-8995 and 20 mg atorvastatin HDL cholesterol levels increased by 152.1%

194 6 months of atorvastatin improved cough on a quality-of-life scale i

195 events by 80 mg/d atorvastatin over 10 mg/d atorvastatin in 4599 patients of the Treating to New Tar

196 ectiveness of a dentifrice medicated with 2% atorvastatin in improving clinical periodontal parameter

197 eline IL-6 concentration and continuation of atorvastatin in this cohort was associated with improved

198 n) or antiepileptogenic affect (for example, atorvastatin) in recognised rodent models or patients.

199 rocess was applied to a concise synthesis of atorvastatin, in which the key 1,6-boration was performe

200 Here we report that high dose atorvastatin increased the phagocytic function of ARPE-1

201 flow and angiogenesis in cirrhosis, whereas atorvastatin increased these parameters in PPVL rats.

202 Ex vivo incubation of RAA samples with atorvastatin induced a mevalonate-reversible and Rac1-me

203 Atorvastatin inhibited the non-canonical Hh-pathway and

204 Atorvastatin is a potent immunomodulatory agent that hol

205 lesions of hypercholesterolemic zebrafish by atorvastatin is notably consistent with the known pharma

206 xposure to different statins (lovastatin and atorvastatin) led to a spatial disorganization of LOX-1

207 Whereas evolocumab but not atorvastatin lowered the concentration of free PCSK9, at

208 tin lowered the concentration of free PCSK9, atorvastatin lowered the lathosterol/campesterol ratio (

209 atin 40-<80 mg), and 12.9% low-dose statins (atorvastatin <20 mg, rosuvastatin <10 mg, simvastatin <4

210 Atorvastatin may exert antiinflammatory effects on phosp

211 low-potency, a high-potency statin, such as atorvastatin, may be necessary in patients with signific

212 NSPT plus 2% atorvastatin medicated dentifrice was more effective in

213 The mechanisms by which atorvastatin modifies myocardial redox state were invest

214 Mean change in FIB-4 score with atorvastatin (n = 944) and fluvastatin (n = 34) was -0.1

215 (4D) who were randomized to either 20 mg of atorvastatin (n=519) or placebo (n=511).

216 double-blind trial to evaluate the impact of atorvastatin on arterial inflammation.

217 irst, we investigated the in vivo effects of atorvastatin on CIAKI.

218 e further validated the beneficial effect of atorvastatin on graft survival by retrospective analysis

219 torvastatin and 223 participants assigned to atorvastatin only.

220 apib plus atorvastatin arm compared with the atorvastatin-only arm by 1.08% (P=0.0004).

221 mg TA-8995 plus 10 mg rosuvastatin or 20 mg atorvastatin or 10 mg rosuvastatin alone.

222 rolemia, adding SAR236553 to either 10 mg of atorvastatin or 80 mg of atorvastatin resulted in a sign

223 Myalgic subjects on atorvastatin or placebo had decreased muscle strength in

224 se A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symp

225 y assigned (1:1) to 1 year of treatment with atorvastatin or placebo.

226 ar rate by participants randomly assigned to atorvastatin or placebo.

227 In total, 299 patients taking atorvastatin or rosuvastatin were prospectively recruite

228 olesterolemia or taking the highest doses of atorvastatin or rosuvastatin, with an overall AE profile

229 evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or witho

230 on of major cardiovascular events by 80 mg/d atorvastatin over 10 mg/d atorvastatin in 4599 patients

231 ng to New Targets (TNT) study and by 80 mg/d atorvastatin over 20-40 mg/d simvastatin in 6541 patient

232 nthly) or ezetimibe (10 mg or placebo daily; atorvastatin patients only) when added to statin therapi

233 When added to atorvastatin, PCSK9 inhibition with SAR236553 further re

234 3, as compared with 17.3+/-3.5 with 80 mg of atorvastatin plus placebo (P<0.001) and 66.2+/-3.5 with

235 ared with 52% of those who received 80 mg of atorvastatin plus placebo, attained an LDL cholesterol l

236 , as compared with 17% who received 80 mg of atorvastatin plus placebo, attained LDL cholesterol leve

237 LDL cholesterol was 73.2+/-3.5 with 80 mg of atorvastatin plus SAR236553, as compared with 17.3+/-3.5

238 acebo (P<0.001) and 66.2+/-3.5 with 10 mg of atorvastatin plus SAR236553.

239 reduction was significant in patients using atorvastatin, pravastatin, and simvastatin.

240 ond, we investigated the in vitro effects of atorvastatin pretreatment on CM-mediated modifications o

241 load and a short-term reload with high-dose atorvastatin protects against early ischemic cerebral ev

242 ac Outcomes Trial (ASCOT, n = 155), 12-month atorvastatin reduced circulating miR-122.

243 Compared with placebo, atorvastatin reduced median sPLA(2) mass (-32.1% versus

244 Atorvastatin reduced non-calcified coronary plaque volum

245 Atorvastatin reduced the hazard of death associated with

246 tertiles confirmed this effect modification: atorvastatin reduced the risk of reaching the primary en

247 High-dose atorvastatin reduces periodontal inflammation, suggestin

248 Atorvastatin reduces the incidence, the severity and the

249 p=0.005; n=37) decreased significantly with atorvastatin relative to placebo.

250 d given 6 h before intervention and either a atorvastatin reload (n = 76; 80 mg + 40 mg initiating 12

251 % in the 300-mg group; p = 0.019) and in the atorvastatin reload arm (18.4% vs. 35.0% in the no stati

252 clopidogrel load and a short-term, high-dose atorvastatin reload would improve outcomes in clopidogre

253 to either 10 mg of atorvastatin or 80 mg of atorvastatin resulted in a significantly greater reducti

254 y lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell

255 onstrated with three different statin drugs (atorvastatin, rosuvastatin, and fluvastatin).

256 dividual cholesterol absorption rate affects atorvastatin's effectiveness to reduce cardiovascular ri

257 ar Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) used serial intravascular ultrasou

258 ater extent than did high-dose atorvastatin, atorvastatin seems to have more renoprotective effects f

259 High-dose atorvastatin significantly reduces sPLA(2) and Lp-PLA(2)

260 nificantly lower among participants assigned atorvastatin than assigned placebo (149 [1.00% per annum

261 end of follow-up, EAT regressed more in the atorvastatin than in the pravastatin group (median, -3.3

262 xercise capacity with atorvastatin, but more atorvastatin than placebo subjects developed myalgia (19

263 nt (n = 199) were randomly assigned 80 mg of atorvastatin the day before surgery, 40 mg of atorvastat

264 vastatin the morning of surgery and 40 mg of atorvastatin the morning after (n = 206) or matching pla

265 of surgery, were randomly assigned 80 mg of atorvastatin the morning of surgery and 40 mg of atorvas

266 torvastatin the day before surgery, 40 mg of atorvastatin the morning of surgery, and 40 mg of atorva

267 ntification of positional isomers of hydroxy-atorvastatins, the primary metabolites of the drug atorv

268 ascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol

269 Atorvastatin therapy in severe sepsis did not affect IL-

270 After 6 months of atorvastatin therapy, the median LDL-C and CRP were redu

271 n patients with LDL-C >/=100 mg/dl on stable atorvastatin therapy.

272 holesterolemia and LDL-cholesterol on Stable Atorvastatin Therapy; NCT01288443).

273 sterol ratios, predicts the effectiveness of atorvastatin to reduce cardiovascular risk in hemodialys

274 imaging was performed on control (n = 9) or atorvastatin-treated mice (0.01% w/w, n = 9).

275 refore, reduced (99m)Tc-cAbVCAM1-5 uptake in atorvastatin-treated mice was successfully monitored non

276 ptake was significantly reduced in 35-wk-old atorvastatin-treated mice, as indicated by ex vivo gamma

277 sured LDL cholesterol levels in the combined atorvastatin-treated populations to 77.5 mg per decilite

278 strate in a randomized controlled trial that atorvastatin treatment can effectively lower 27-hydroxyc

279 ing cardiac surgery, high-dose perioperative atorvastatin treatment compared with placebo did not red

280 (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting [A

281 Moreover, atorvastatin treatment for 12 weeks reduced target-to-ba

282 Pre-operative atorvastatin treatment suppressed atrial NADPH oxidase a

283 .039), but not in the group that intensified atorvastatin treatment to 80 mg (p = 0.24).

284 ict the effects of a subset of inhibitors on atorvastatin uptake in vivo.

285 OATP1B1 and OATP1B3 as major determinants of atorvastatin uptake in vivo.

286 d 9899 patients in this analysis (6409 [65%] atorvastatin users and 3490 [35%] non-users), with a med

287 an change of 1.5 units in patients allocated atorvastatin versus -0.7 units in those assigned placebo

288 elial cyclooxygenase-2 (COX-2), increased by atorvastatin via S-nitrosylation of COX-2 and reduced by

289 Arg allele, the HR for high- versus low-dose atorvastatin was 0.81 (95% confidence interval, 0.59-1.1

290 Furthermore, atorvastatin was able to block the induction of interleu

291 Atorvastatin was associated with a reduced risk of incid

292 Administration of atorvastatin was associated with plaque stabilization an

293 A similar response to atorvastatin was observed in mice and cultured murine he

294 termination of the trial because efficacy of atorvastatin was shown), all patients were offered atorv

295 ion term between tertiles and treatment with atorvastatin was significantly associated with the risk

296 Atorvastatin was the most commonly prescribed statin (73

297 rption appear to benefit from treatment with atorvastatin, whereas those with high absorption do not

298 mits of this study, it can be concluded that atorvastatin, which is used for hypercholesterolemia tre

299 alene cyclase inhibitors in combination with atorvastatin while maintaining selectivity against endot

300 reproduced by simvastatin, whereas combining atorvastatin with cyclosporine or mycophenolate in place

301 e, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly red